Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The firm also focuses on developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury. The company was founded by Graham Edmund Kelly on August 29, 2017 and is headquartered in Gordon, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company